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ABSTRACT
Objective: Psychiatric evaluation of 50 essential 
tremor (ET) patients was performed to determine 
the coexistent psychopathologies. The patients 
with positive psychopathologies were intended to 
treat by appropriate medication to demonstrate a 
positive effect of the treatment to tremor severity.
Methods: Symptom check list (SCL - 90R) and 
structural clinical interview-nonpatient (SCID-NP) 
were used as screening tests for 
psychopathologic symptoms. The patients with 
positive psychiatric findings according to DSM IV 
criteria were asked to use appropriate medication 
for 6 weeks in addition to their antitremor drugs. 
Alprazolam 0.75 mg daily was used for 
generalized anxiety disorder and social phobia, 
and sertraline 50 mg daily was given for affective 
disorder. Tremor severity was assessed by a 
standard scale before and after treatment.
Results: The results revealed the presence of 
anxiety disorder in 42 %, social phobia in 18 %, 
and affective disorder in 16 % of the patients. 
Administration of alprazolam to patients with 
anxiety disorders demonstrated a statistically 
significant improvement in tremor severity 
(p<0.05), however, in patients with social phobia 
and affective disorders no significant
improvement was observed after alprazolam or 
sertraline treatment, respectively.
Conclusion: Although the present study lacked 
a post-treatment psychiatric evaluation and had a 
limited study period of 6 weeks to identify the 
effect of present psychopathology on tremor 
severity, the observed frequent coexistence of 
psychopathologies and ET was quite 
remarkable. The results reinforced the positive 
effect of alprazolam on tremor control of ET 
patients with anxiety disorder. However, we 
could not demonstrate a significant improvement 
in tremor severity following treatment in ET 
patients having social phobia or dysthimic 
symptoms.
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INTRODUCTION
Essential tremor (ET) is the most common 
movement disorder encountered in neurology 
clinics. Tremor can be affected by several 
factors, and it is not unusual for patients to 
associate the onset of tremor with a specific 
incident or circumstance. Furthermore, in the
(A c c e p ted  23  May, 2 0 0 1 )  M arm ara  M ed ica l  J o u rn a l  2001 ;1 4 (3 ) :1 65-168
Correspondence to: Dilek ince Günal, M. D. - Department of Neurology, Marmara University Hospital,
Tophanelloğlu Cad. 81190 Altunizade - İstanbul, Turkey, 
e.mail address: incegunal@yahoo.com
1 6 5
Dilek Ince Gunal, et al
intervening years a number of specific factors like 
emotional stress may exacerbate ET (1). In this 
respect, psychiatric evaluation of ET patients 
might play a role in the management and follow 
up of these patients. The aim of this study was to 
screen ET patients with standard psychiatric 
interview and self-reported questionnaire, 
followed up with appropriate treatment protocols, 
either antidepressive or anxiolytic agents for 6 
weeks, in order to clarify the coexistence of 
psychological pathologies and the effect of these 
on tremor severity.
METHODS
Fifty consecutive patients were recruited from a 
movement disorder outpatient clinic of a 
University Hospital. All patients had a diagnosis 
of definite or probable ET based on the Tremor 
Research Investigation Group Criteria (2). Thirty- 
eight of 50 patients were on primidone with a 
mean daily dose of 167.2 mg (range 62.5-375), 
and 12 were on propranolol with a mean daily 
dose of 42 mg (range10-60). A written informed 
consent was obtained from all patients and the 
study protocol was approved by the Ethics 
Committee of the Medical School. As 
psychological instrument, SCL-90R (Symptom 
Check List) (3) was used as screening test for 
psychopathologic symptoms. Nine subscales 
were included in the test such as somatization, 
obsessive-compulsive symptoms, depression 
and interpersonal sensitivity . General symptom 
index was used to measure the severity of the 
symptoms. SCID-NP (Structural clinical 
interview- nonpatient) was used to evaluate 
current depressive episodes, past major 
depressive episodes, current and past manic 
episodes, current dysthimia, psychotic symptoms 
and disorders, psychoactive substance related 
disorders, general anxiety disorders (panic 
disorder and social phobia), obsessive- 
compulsive disorders and eating disorders. The 
patients with positive psychiatric findings 
according to DSM IV criteria (4) were asked to 
use appropriate medication for 6 weeks in 
addition to their antitremor drugs. Alprazolam
0.75 mg daily was used for generalized anxiety 
disorder and social phobia, and sertraline 50 mg 
daily was given for affective disorder.
Tremor severity was assessed by a scale 
including 4 functional items namely: writing a
sentence and drawing a spiral, each rated from 
0 to 4 (0: normal, 4: unable to keep pencil on 
paper) ; feeding ( 0: normal, 4: needs help to 
feed) and social activity ( 0: normal, 3: severe 
without social activity). Patients also self-rated 
global improvement on a scale of 0 to 3 (0: no 
tremor, 3: no change). Tremor assessment was 
repeated at the end of the 6 week period, and pre 
and post-treatment tremor scores were analyzed 
by nonparametric Wilcoxon test.
Significant difference between groups was 
assumed at an a = 0.05.
RESULTS
There were 32 men and 18 women with a mean 
age of 52.2 (18-75), and with a mean disease 
duration of 6.2 (3-25) years. All patients had 
hand tremor , 5 with additional head tremor and 
3 with voice tremor. No dropout was recorded 
during the study period, and the medications 
were well-tolerated without any significant side 
effect.
During interviews, 11 of 50 patients (23%) 
reported a visit to a psychiatrist, and 19 of these 
(38%) had experienced major depressive 
episodes in the past. Anxiety disorder was found 
in 21 patients (42 %), and at the end of 
alprazolam therapy lasting 6 weeks, a significant 
29.2 % (p<0.05) improvement was observed in 
tremor severity.(Fig. 1).
Affective symptoms reported by the patients did 
not reach the threshold of a major depressive 
episode at the end of psychiatric assessment, 
and the degree of symptoms was best titled into 
a borderline condition. This condition is 
described as a chronically depressed mood that 
lasts for most of the day over a period of for at 
least 2 years, and is categorized as dysthimia
(4). Six of 50 patients (16 %) were evaluated as 
dysthimic. Sertraline therapy lasting 6 weeks did 
not cause a significant change in tremor scores 
(p= 0.078) (Fig. 1).
Social phobia was diagnosed in 9 cases (18%), 
and alprazolam produced a 9.1% reduction in 
tremor scores, although the difference fell 
just short of statistical significance (p=0.069) 
(Fig. 1).
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F i g .1 :
The effect of 
psychopathology-related 
medication on the tremor 
severity. Medications: 
alprazolam for anxiety 
disorders and social 
phobia, sertraline for 
dysthimia.
DISCUSSION
The present study discloses the presence of a 
psychopathology such as anxiety, social phobia 
and depression, in thirty-six of 50 (76 %) ET 
patients. Anxiety was present in 42 %, dysthimia 
in 16 %, and social phobia in 18 % of the 
patients. None of the patients reported any form 
of substance abuse or dependency despite the 
high percentage of generalized anxiety disorder 
and social phobia. This might be due to the 
cultural non-acceptance of alcohol or any other 
substance although the therapeutic effect of 
alcohol on ET was known by most of the patients 
(5,6).
The psychiatric evaluation of patients was quite 
frequently pathologic, however there was not 
enough data to estimate if these pathologies 
were secondary to their tremor. Anxiety disorder 
was the most common amongst those, and the 
combination of an anxiolytic agent with anti­
tremor medication resulted in 29.2 %
improvement in tremor severity. The 
effectiveness of alprazolam on ET has been 
shown in two double blind, placebo-controlled 
studies (7,8). Likewise, the present study 
reinforced the positive effect of alprazolam on 
tremor control of ET patients with anxiety 
disorder. Although the mechanism of the action 
of alprazolam anti-tremor effect is still not clear, 
its well recognized anxiolytic effect seems to be 
the most likely explanation.
Several recent surveys have documented the 
high prevalence of social phobia as symptom
secondary to ET (9,10). Pharmacological 
intervention of social phobia showed a tendency 
to decrease tremor severity (9.1 % reduction in 
tremor scores) in our patients, without reaching 
statistical significance. Furthermore, as the 
psychological evaluation was not repeated at the 
end of the six weeks, we cannot ascertain 
whether social phobia was treated properly in all 
patients. Moreover, additional behavioral 
approaches should have been applied together 
with alprazolam to determine, more reliably, the 
potential role of social phobia on ET.
The clinical reports of affective spectrum was one 
of the most challenging parts of the psychiatric 
assessment in the present study. Dysthimia was 
found in16 % of the patients and sertraline, a 
serotonin reuptake inhibitor, was used for the 
treatment. Tremor scores of the patients did not 
show significant improvement after sertraline 
treatment, however, whether this is due to 
abscence of relation between dysthimia. and 
tremor severity or if the antidepressant therapy 
was ineffective cannot be ascertained.
Other movement disorders, such as essential 
blepharospasm and hemifacial spasm, rather 
than ET, were studied for the presence of 
psychopathologic symptoms by Scheldt et al
(11). Their results indicated that severe 
psychopathologic symptoms were not a 
prominent feature of these diseases, but they 
found increased phobic anxiety to be probably a 
consequence of neurological disability. In 
contrast, the coexistence of ET, and 
psychopathologies has not been studied
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extensively. The present study revealed the 
existence of anxiety disorders, social phobia and 
affective disorders coexistent with ET. Whether 
the psychopathologies are illness-related, and 
secondary or pathologic personality traits cause 
ET is a challenging issue.
Either secondary to the disease itself or primary, 
psychopathologies in ET patients can be 
encountered as a whole, and appropriate 
medication can be applied to treat these 
symptoms. Although treatment of anxiety was 
demonstrated to improve tremor severity in the 
present study, no significant difference on tremor 
could be demonstrated in patients with dysthimia 
and social phobia after administration of 
treatment protocol. With limitations such as lack 
of post-treatment psychiatric evaluation and a 
rather brief study period, we might only remark 
on the quite common coexistence of some 
psychopathologies and ET. Randomized, 
controlled studies are needed to estimate the 
effect of underlying psychopathologies on tremor 
severity.
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